Michael R. Harrison, MD, discusses several ongoing or upcoming studies that may change the treatment paradigm in renal cell carcinoma.
Michael R. Harrison, MD
Advertisement
Articles by Michael R. Harrison, MD
Michael R. Harrison, MD, discusses common toxicities associated with immuno-oncology–based combinations and their effects on treatment selection in renal cell carcinoma.
Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses choosing frontline treatment for patients with renal cell carcinoma (RCC).
Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses the possibility of nivolumab (Opdivo) plus ipilimumab (Yervoy) becoming the new interleukin-2 (IL-2).
Advertisement
Latest Updated Articles
Dr. Harrison on the Possibility of Nivolumab Plus Ipilimumab Becoming the New IL-2Published: October 20th 2017 | Updated:
Dr. Harrison on Choosing Frontline Treatment for RCCPublished: December 1st 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 1/25
2
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5